tbuckley/cabot-search huggingface dataset:
Possibly a hero, but not a medical one
Authors: J. Gilbert
Journal: BMJ (1996)

EDITOR,—John Roberts and Carl Kjellstrand's editorial contains several uncontroversial assertions: that those who are dying need our commitment to stay with them throughout their journey, that few of those who write about ethics and decisions concerning the end of life have direct responsibility to people in need, and that Jack Kevorkian has been a man of action who has lived by a personal code of honour …
Abstract 3416: Incremental Diagnostic Utility of Contrast-Enhanced MRI (CE-MRI) vs Contrast Echocardiography for Detection of Left Ventricular Thrombus: Morphologic Predictors of Improved Thrombus Detection by CE-MRI in Patients with Systolic Dysfunction
Authors: Daniel G Krauser, Michael Ross, James K Min, Matthew D Cham, Mary J Roman, Ingrid Hriljac, Jorge R Kizer, Han W Kim, Igor Klem, Raymond J Kim, Richard B Devereux, Jonathan W Weinsaft
Journal: Circulation (2007)

Background Accurate detection of left ventricular thrombus (LVT) affects clinical management of at risk pts. CE-MRI identifies LVT based on tissue characteristics and has been validated as a highly sensitive technique that improves LVT detection vs non-contrast echo. However prior comparative studies were performed without echo contrast agents, which can improve echo LVT detection. We studied diagnostic performance of contrast (C-ECHO) and non-contrast echo (NC-ECHO) vs a reference of CE-MRI for LVT detection. Methods We prospectively enrolled pts with ejection fraction (EF) &lt;50% referred for CE-MRI (1.5 T) to evaluate for LVT. NC-ECHO and C-ECHO (Definity; perflutren lipid microspheres) were performed within 7 (mean 1.2 ± 1.6) days of CE-MRI. Studies were interpreted blinded to results of the other modality. LVT were scored for location, volume and type (mural or intracavitary). EF was measured by cine-MRI planimetry. Cine and CE-MRI were scored via a 17 segment model to quantify wall motion and scar. Results 80 pts were studied (age 63 ± 13, 90% CAD, NYHA 2.4 ± 0.7). CE-MRI identified LVT in 25 pts (31%). 84% of LVT were apically located; 32% were mural. All LVT were adjacent to myocardial scar. Pts with LVT by CE-MRI had larger transmural scar size (25 vs 16% of LV segments; p = 0.01) but similar EF (30 vs 33%; p = 0.4) and wall motion score index (2.3 vs 2.1; p = 0.4) to those without LVT. C-ECHO had nearly 2 fold higher diagnostic sensitivity (p = 0.02) and improved accuracy (p = 0.02) vs NC-ECHO (table ). However, C-ECHO did not detect 32% of LVT identified by CE-MRI. LVT missed by C-ECHO were more likely to be mural (p &lt; 0.01). Apically located LVT were more likely to be missed when small (0.9 vs 4.1 cm3; p = 0.01) while detection of non-apical LVT was independent of size. Conclusions While echo contrast improves diagnostic performance for LVT, a substantial number of LVT identified by CE-MRI are not detected by C-ECHO. LVT missed by C-ECHO are typically mural in shape or, if apical, small in volume. Left Ventricular Thrombus Detected by CE-MRI (n = 25)
Abstract 15439: High Rates of antiplatelet Use in Atrial Fibrillation Patients Treated With Oral Anticoagulation: Insights from the Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry
Authors: Milan K Gupta, Narendra Singh, Jafna L Cox, Paul Dorian, Carl Fournier, G.B. J Mancini, Ashfaq Shuaib, Mahesh Kajil, Michelle Tsigoulis, Andrew C Ha
Journal: Circulation (2014)

Introduction:  Among patients with atrial fibrillation (AF) treated with oral anticoagulation (OAC) for stroke prevention, concomitant use of antiplatelet (AP) agents increases bleeding risk and may not be associated with a significant reduction in the rates of vascular events. We sought to identify factors associated with OAC+AP vs. OAC use in a contemporary AF registry.   Methods:  From December 2012 to July 2013, a cross-sectional analysis of 936 consecutive AF patients was performed. They were enrolled from 109 community practices (84 [77%] Primary Care practices) in 10 Canadian provinces. Demographics of patients treated with OAC+AP (primarily aspirin) vs. OAC alone were identified. Multivariable logistic regression was performed to identify factors associated with OAC+AP vs. OAC use.   Results:  Seven hundred and eighty-two (83.1%) patients were treated with OAC, amongst whom 143 (18.3%) were treated with OAC+AP and 639 (81.7%) were treated with OAC alone. Amongst patients treated with OAC+AP, 59 (41.3%) did not have a history of coronary artery disease (CAD) (defined as history of stable CAD, acute coronary syndrome, percutaneous coronary intervention (PCI), or coronary artery bypass surgery) or peripheral arterial disease (PAD). In the OAC+AP group, 41 (28.7%) patients had PCI, 55 (38.5%) patients had diabetes, and 24 (16.8%) patients had a previous stroke or transient ischemic attack. Patient treated with OAC+AP vs. OAC alone did not significantly differ in age: 76.7 (71.2, 82.9) vs. 76.8 (69.5, 83.1) years (median, IQR). On multivariable analysis, CAD (OR 3.60, 95% CI 2.24 to 5.55, p   Conclusions:  In this contemporary AF registry, about 1 in 5 OAC-treated patients was also treated with AP. Although a history of CAD was associated with OAC+AP use, about 40% of patients did not have compelling indications for being treated with AP agents. The relatively high rate of concomitant AP use in OAC-treated AF patients presents a potential opportunity to reduce major bleeding. Efforts are needed to address this practice pattern to minimize over-prescription of AP in this population.
A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization
Authors: Armando Lopez-Guillermo, Miguel A. Canales, Ivan Dlouhy, Javier Briones, Dolores Caballero, Juan Manuel Sancho, Santiago Mercadal Vilchez, Jose María Moraleda, María José Terol, Antonio Salar, Luis Palomera, Santiago Gardella, Isidro Jarque, Secundino Ferrer, Joan Bargay, Andres Lopez, Carlos Panizo, Anna Muntanola, Carlos Montalban, Eulogio Conde, Miguel Hernandez, Alfons Soler, Julian Marin, Jose García Marco, Guillermo Deben, José Francisco Tomas
Journal: Blood (2013)
Abstract 15583: Evaluation of the Efficacy of Aminaftone in a Rat Model of Monocrotaline-induced Pulmonary Hypertension
Authors: Francesca Fumagalli, Vanessa Zambelli, Serge Masson, Alessandro Santaniello, Margherita Scanziani, Raffaella Scorza, Roberto Latini
Journal: Circulation (2010)

Introduction: Increased vascular resistances give rise to pulmonary arterial hypertension (PAH), leading to right heart failure and death. The main mediator of PAH is endothelin-1 (ET-1), a peptide...
心力衰竭（三）辅助检查
Authors: 严红
Journal: BMJ (2001)

对疑诊为心力衰竭 (心衰 )的患者 ,须进行详细的辅助检查 ,而后才做临床评估。由于心衰的特异性临床表现常缺如 ,只有与客观的检查尤其是超声心动图相结合 ,才能准确地诊断。现在 ,超声心动图检查越来越方便易行 ,而更准确的检查还应包括胸部Ｘ线、12导联心电图和肾功能检查。 胸部Ｘ线检查 对疑诊心衰者 ,胸部Ｘ线是一项重要的常规检查 ,且可用于监测对治疗的反应。Ｘ线检查可以发现心影增大 (心胸比例 >5 0 % ) ,但心胸比例与左室功能之间的相关性较差。心影增大与否 ,取决于血流动力学障碍严重程度及其病程。例如 ,在继发于急性心肌梗死、急性瓣膜关闭不全或获得性室间隔缺损的急性左心衰竭中
Abstract 1498: Do Fibrates Reduce Cardiovascular Mortality? A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Authors: Mouaz Al-Mallah, Rachid Lakhdar, Mohamad Sinno, Muhamad Arida, Ahmad Abdelatif, Imad Tleyjeh
Journal: Circulation (2006)

Background: The evidence for fibrates use in patients with established or presumed coronary artery disease (CAD) has been conflicting. We thought to systematically review the literature and perform...
Abstract 15791: Increased Oxygen Content and Decreasing Oxygen Affinity of Hemoglobin Based Oxygen Carrier (HBOC) Reperfusate Can Improve Myocardial Function and Preserve Myocardium Following Global Ischemia
Authors: Daniel Zelinski, Yipin Zhou, Ande Palmer, Mark Angelos
Journal: Circulation (2011)

Background: Hemoglobin based oxygen carriers (HBOC) offer a potential adjunct to improve early re-oxygenation of ischemic tissue. However, the optimal oxygen content and oxygen affinity of the HBOC...
Ga-67 and Tl-201 scintigraphy in extramedullary plasmacytoma: a case report.
Authors: JOHAN WIJAYA, DAVID McHARG
Journal: Clinical Nuclear Medicine (2001)

Extramedullary plasmacytoma is a rare form of plasma cell tumor occurring in a wide variety of organs and tissues. Most tumors occur in the head and neck, involving the nasal cavity, paranasal sinuses, and upper airway. Tl-201 and Ga-67 scan findings in a patient with extramedullary plasmacytoma in the right side of the chest wall are presented. Only a few publications have described Tl-201 or Ga-67 uptake in extramedullary plasmacytoma. This is the first report of both Tl-201 and Ga-67 uptake in an extramedullary (or intramedullary) plasmacytoma.
THE AMERICAN MEDICAL DIRECTORY.
Authors: John B. Balkema
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Management of Acute Lower Gastrointestinal Haemorrhage in a Surgical Unit Over a 4-Year Period
Authors: P A Farrands, I Taylor
Journal: Journal of the Royal Society of Medicine (1987)

Over a 4-year period 107 patients, 5% of all emergency admissions, were admitted to one surgical unit with significant lower gastrointestinal haemorrhage (requiring more than a 2-unit transfusion of blood). Twenty-three individuals required more than 3 units of blood, and 7 life-saving surgery. All subjects undergoing surgery required more than 3 units of blood in the first 24 hours of admission. Arteriography was diagnostic in 5 of the 9 subjects in whom it was performed. Arteriography was positive if performed in the first 24 hours of admission. A flow chart of the management of patients with lower gastrointestinal haemorrhage is presented.
A Real-Time and Dynamic Biological Information Retrieval and Analysis System (BIRAS)
Authors: Qi Zhou, Hong Zhang, Meiying Geng, Chenggang Zhang
Journal: Genomics Proteomics & Bioinformatics (2003)

Abstract The aim of this study is to design a biological information retrieval and analysis system (BIRAS) based on the Internet. Using the specific network protocol, BIRAS system could send and receive information from the Entrez search and retrieval system maintained by National Center for Biotechnology Information (NCBI) in USA. The literatures, nucleotide sequence, protein sequences, and other resources according to the user-defined term could then be retrieved and sent to the user by pop up message or by E-mail informing automatically using BIRAS system. All the information retrieving and analyzing processes are done in real-time. As a robust system for intelligently and dynamically retrieving and analyzing on the user-defined information, it is believed that BIRAS would be extensively used to retrieve specific information from large amount of biological databases in now days. The program is available on request from the corresponding author.
Sox9, a marker of chondrocyte differentiation, is over-expressed in uterine malignant mixed mullerian tumor
Authors: Zaina Sangale, Russell Broaddus
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

5496 

Background: Malignant mixed mullerian tumors (MMMT) of the uterus are poorly differentiated tumors composed of malignant epithelial and malignant mesenchymal components. MMMT are aggressive neoplasms, associated with advanced stage at diagnosis and a poor prognosis. In contrast, well-differentiated, low grade endometrioid endometrial carcinomas are typically associated with good prognosis. Significant progress has been made in defining the molecular events associated with endometrioid carcinoma. The molecular pathogenesis of non-endometrioid tumors, such as MMMT, remains poorly understood. A clue to molecular mechanisms important in MMMT is derived from careful pathologic examination of these tumors. We have observed that in most cases of MMMT, the malignant mesenchymal component closely resembles poorly differentiated, high grade chondrosarcoma. We therefore hypothesized that molecular mediators of chondrocyte biology play a role in uterine MMMT. The transcription factor Sox9 is an important regulator of chondrogenesis and has been previously demonstrated to be selectively expressed in mesenchymal chondrosarcomas. Therefore, the purpose of this study was to examine the expression of Sox9 in uterine MMMT and compare it to expression in well-differentiated, grade 1 endometrioid carcinoma.    Design: Sox9 immunohistochemistry was semi-quantitatively examined in 13 cases of benign proliferative and secretory endometrium, 13 uterine grade 1 endometrioid adenocarcinomas, and 18 uterine MMMT. For the MMMT, cases were selected in which both the malignant epithelial and malignant mesenchymal components were present.    Results: In all cases of normal endometrium, nuclear Sox9 expression was confined to epithelial cells of the stratum basalis, where the expression was usually weak. In biopsies of normal endometrium, in which usually the superficial endometrium is sampled, no Sox9 expression was observed. Only 3/13 (23%) of the grade 1 endometrioid tumors had diffuse (>40% of slide) Sox9 expression; the remainder had focal or no expression of Sox9. Fifty per cent (9/18) of the MMMT's had diffuse (> 40%) Sox9 expression; overall, Sox9 expression was much higher in MMMT than grade 1 endometrioid tumors. In MMMT, Sox9 was expressed in both the malignant epithelial and malignant mesenchymal components.    Conclusion: These results support the hypothesis that molecular mediators of chondrogenesis are over-expressed in uterine MMMT compared to low-grade endometrioid tumors. Interestingly, Sox9 was expressed in both the carcinomatous and sarcomatous components of MMMT. The Sox9 expression pattern in normal endometrium is interesting in that the basalis layer is the portion of the endometrium that is retained following cyclical menstruation; this layer likely harbors endometrial stem cells. Accordingly, Sox9 expression has been associated with stem cell compartments in other tissues.
Abstract 12089: Human Umbilical Cord Blood Cells Secrete Growth Factors and Cytokines that Inhibit Hypoxic-induced Apoptosis in Human Coronary Artery Endothelial Cells and Cardiac Myocytes by Activation of the Survival Proteins Akt and Bcl-2
Authors: Hua Jin, Robert J Henning, Paul Sanberg
Journal: Circulation (2012)
Abstract 1596: Detection of PD-L1 in cell surface vimentin positive circulating tumor cells is associated with poor survival in cancer patients
Authors: Arun Satelli, Zachary Brownlee, Hyangsoon Noh, Qing H. Meng, Scott Kopetz, Michael Overman, Shulin Li
Journal: Cancer Research (2015)

Abstract Circulating tumor cells (CTCs) are the cells that detach from the primary tumor of patients and enter in to the blood stream and these can be represented as the seeds of metastasis. Increasing evidence has shown the detection of circulating tumor cells (CTCs) from blood of cancer patients parallels with tumor burden and is associated with poor prognosis. Although CTC counts change indicates a good modality to detect therapeutic response to drug treatments, there is an increasing need of a reliable marker that can be used to predict survival in cancer patients. One of the most prevalent markers detected in cancer patients is the cell surface glycoprotein called PD-L1 (also called B7-H1 and CD274). Aberrant expression of PD-L1 has been reported in several cancer types. Here in this study we tested the hypothesis that detection of PD-L1 in CTCs is associated with poor prognosis. To validate the hypothesis, we isolated cell-surface vimentin (CSV) positive CTCs from colorectal cancer patients using 84-1 method and analyzed for PD-L1 expression. Our results indicated that PD-L1 detection in CTCs was associated with poor overall survival (HR, 2.43; 95% CI, 1.11 to 5.35; p, 0.0264) in colorectal cancer patients undergoing treatment. These findings thus suggest that PD-L1 detection in CSV CTC could serve as a new prognostic tool. We further extend our observations in other types of cancers including breast, prostate and sarcoma. Citation Format: Arun Satelli, Zachary Brownlee, Hyangsoon Noh, Qing H. Meng, Scott Kopetz, Michael Overman, Shulin Li. Detection of PD-L1 in cell surface vimentin positive circulating tumor cells is associated with poor survival in cancer patients. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1596. doi:10.1158/1538-7445.AM2015-1596
Great diversity of tuberculosis treatment in Finland
Authors: T Vasankari, M Kokki, P Holmström, K Liippo, S Sarna, P Ruutu
Journal: Eurosurveillance (2007)

We investigated the treatments given and the outcome in a national cohort of culture-verified pulmonary tuberculosis cases in Finland. Our aim was to find out how adequate TB treatment was, and the outcome of treatment. Medical records of all culture-verified pulmonary tuberculosis cases in 1995 - 1996 were abstracted to assess treatment and outcome, using the European recommendations for outcome monitoring.
Fact sheets may be useful
Authors: M. Rosen
Journal: BMJ (1995)

EDITOR,—John Mitchell and others discuss what seems an amazing decision by the General Medical Council's professional conduct committee.1 A consultant anaesthetist practising as his peers do was found guilty of insufficient explanation, assault on the patient, and serious professional misconduct beyond reasonable doubt; the dentist was also similarly found guilty by the General Dental Council. Although this seems outrageous, we should read the transcripts carefully before reaching any conclusion. It is implied that these decisions go beyond just the use …
Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura
Authors: Joel L. Moake, John J. Byrnes, Joseph H. Troll, Christine K. Rudy, Suchen L. Hong, Mark J. Weinstein, Noreen M. Colannino
Journal: Blood (1985)
Abstract 13485: Prevalence and Treatment of “Balloon Uncrossable” Coronary Chronic Total Occlusions
Authors: Siddharth Patel, Nagendra Pokala, Rohan Menon, Anna Kotsia, Vijay Raja, George Christopoulos, Tesfaldet Michael, Bavana Rangan, Daniel Sherbet, Vishal Patel, Shuaib Abdullah, Jeffrey Hastings, Jerrold Grodin, Subhash Banerjee, Emmanouil Brilakis
Journal: Circulation (2014)

Background: In percutaneous coronary intervention (PCI) of coronary chronic total occlusions (CTOs), inability to cross the lesion with a balloon is the second most common cause of technical failure following inability to cross the lesion with a guidewire. While various techniques have been reported for such "balloon uncrossable" CTOs, the frequency and outcomes of these techniques have received limited study. Methods: We retrospectively examined 373 consecutive CTO PCIs performed at our institution between 2005 and 2013 to determine the frequency and outcomes of “balloon uncrossable” CTOs. Results: Mean age was 63.7 ± 8.3 years and 98.9% of the patients were men. Twenty four patients (6.4%) were found to have a "balloon uncrossable" CTO. These patients had similar clinical and angiographic characteristics compared to the other CTO PCI patients (Table). Successful crossing of the lesion was achieved in 22 of 24 patients (91.7%) using a variety of techniques, such as successive balloon inflations (43.5%), microcatheter advancement (21.7%), laser (8.7%), increased guide catheter support (13.0%), and subintimal lesion crossing (13.0%) (Figure). Patients with “balloon uncrossable” CTOs had longer procedure time (184.5 ± 77.9 vs. 134.0 ± 69.0 min, p&lt;0.01), fluoroscopy time (55.2 ± 24.9 vs. 37.9 ± 20.8 min, p&lt;0.01), and received higher contrast volume (404.4 ± 137.9 vs. 351.7 ± 138.5 ml, p=0.085), but had similar incidence of major complications (8.3% vs. 3.2%, p=0.25) compared to patients without “balloon uncrossable” CTOs. Conclusion: “Balloon uncrossable” CTOs occur in 6.4% of contemporary CTO PCIs and can be successfully treated in most patients using a variety of techniques.
Abstract 17636: Safety and Tolerability of Regadenoson Stress CMR
Authors: Kim L Nguyen, W. P Bandettini, Sujata Shanbhag, Steve W Leung, Joel R Wilson, Andrew E Arai
Journal: Circulation (2012)

Background & Objective:   Regadenoson binds selectively to the A(2A) receptor to promote coronary vasodilation during stress testing. It is given as a fixed-dose rapid injection, thus simplifying the dosing regimen compared to adenosine and dipyridamole, obviating the need for an MRI compatible infusion pump. We assessed the safety and tolerability of regadenoson stress CMR.    Materials & Methods:   A group of 726 patients (age 57 ± 12, 56% males, 44% females, 20% diabetic (DM)) were prospectively recruited under an IRB-approved protocol with defined inclusion and exclusion criteria and scanned for clinical indications over a 30-month period. The control group consisted of 25 normal volunteers (age 23 ± 7). Patients were stressed with fixed dose regadenoson and scanned on a 1.5T scanner. Symptoms and major/minor adverse events including death, MI, arrhythmias, and hospitalization were assessed and recorded by the nurse and supervising physician.    Results:   Of the 726 exams, 99% (n=718) were of diagnostic quality. The most common symptoms in patients were dyspnea (30%, n=217), chest discomfort (28%, n=201), and headache (15%, n=111). Palpitations (60%, n=15) and dyspnea (28%, n=7) were common in the control group. Adverse events included bronchospasm (n=3, with one requiring hospitalization), symptomatic hypotension (n=1), contrast extravasation (n=2), and stress-induced SVT (n=1). Minor stress-induced arrhythmias (PVCs and PACs) occurred in 9% (n=67) of all exams. No VT/VF, death, MI, high grade AV block, or stress-induced atrial fibrillation occurred. There was no difference in SBP (p=0.60) and DBP (p=0.82) response, or rate pressure product (RPP) (p=0.33) between the patient vs. the control group. DM patients had a blunted heart rate (HR) response (p=0.002) when compared to non-DM patients despite a higher baseline HR (p=0.013), yet had no difference in SBP (p=0.30) and DBP (p=0.14) response, or RPP (p=0.20). Similarly, patients with abnormal perfusion exams had a blunted HR response (p=0.01), despite having a higher baseline HR (p    Conclusions:   Regadenoson CMR is well tolerated and can be performed safely with few adverse events. In diabetics and those with abnormal perfusion exams, a blunted HR response is noted.